Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.
Bio-Techne said that the firms will collaborate to develop "better and more accurate" point-of-care diagnostic tools for the Chinese market.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
Its platform is being developed for several medical conditions using separate modules to measure cells, proteins, nucleic acids, enzymes, and small molecules.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
Currently marketed for research use by Biofluidica, the test's microfluidic channels use specific cancer antibodies to detect capture circulating tumor cells.
The device consists of a reservoir that enables the analyte to contact only the top of a screen-printed electrode, increasing sensitivity.
The company's microchip-based technology will detect viral and bacterial genetic material using both isothermal amplification and electrochemical measurements.
Researchers at NJIT have initially tested their biochip for the detection of early-stage ovarian cancer, but they said it could have use for other cancers and diseases.